aclarubicin and Hypercalcemia

aclarubicin has been researched along with Hypercalcemia* in 1 studies

Other Studies

1 other study(ies) available for aclarubicin and Hypercalcemia

Article	Year
Parathyroid hormone-related protein as a cause of hypercalcemia in a B-cell type malignant lymphoma. Internal medicine (Tokyo, Japan), 1992, Volume: 31, Issue:8 Hypercalcemia occurred in a patient with non-Hodgkin's (B-cell type) lymphoma when generalized lymphadenopathy developed. Despite low normal plasma parathyroid hormone (PTH), nephrogenous cAMP (NcAMP) was not suppressed, and serum and urine PTH-related protein (PTH-rP) levels were elevated. The plasma level of 1,25(OH)2D was within normal range. The combined chemotherapies successfully reduced the tumor size, serum Ca, PTH-rP, and lactic dehydrogenase. Serum osteocalcin was suppressed while the patient was hypercalcemic, and increased after chemotherapy. In the extract of the tumor tissue obtained post mortem, bioactivity stimulating the production of cAMP in osteoblasts was demonstrated along with the immunoreactive PTH-rP. This is the first report of a B-cell lymphoma producing PTH-rP and its association with humoral hypercalcemia of malignancy. Topics: Aclarubicin; Adult; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Cisplatin; Creatinine; Cyclic AMP; Cytarabine; Etoposide; Glomerular Filtration Rate; Humans; Hydroxycholecalciferols; Hydroxyproline; Hypercalcemia; Ifosfamide; L-Lactate Dehydrogenase; Lymphoma, B-Cell; Male; Osteocalcin; Parathyroid Hormone; Parathyroid Hormone-Related Protein; Prednisolone; Procarbazine; Proteins	1992

Article

Year

Parathyroid hormone-related protein as a cause of hypercalcemia in a B-cell type malignant lymphoma.

Internal medicine (Tokyo, Japan), 1992, Volume: 31, Issue:8

Hypercalcemia occurred in a patient with non-Hodgkin's (B-cell type) lymphoma when generalized lymphadenopathy developed. Despite low normal plasma parathyroid hormone (PTH), nephrogenous cAMP (NcAMP) was not suppressed, and serum and urine PTH-related protein (PTH-rP) levels were elevated. The plasma level of 1,25(OH)2D was within normal range. The combined chemotherapies successfully reduced the tumor size, serum Ca, PTH-rP, and lactic dehydrogenase. Serum osteocalcin was suppressed while the patient was hypercalcemic, and increased after chemotherapy. In the extract of the tumor tissue obtained post mortem, bioactivity stimulating the production of cAMP in osteoblasts was demonstrated along with the immunoreactive PTH-rP. This is the first report of a B-cell lymphoma producing PTH-rP and its association with humoral hypercalcemia of malignancy.

Topics: Aclarubicin; Adult; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Cisplatin; Creatinine; Cyclic AMP; Cytarabine; Etoposide; Glomerular Filtration Rate; Humans; Hydroxycholecalciferols; Hydroxyproline; Hypercalcemia; Ifosfamide; L-Lactate Dehydrogenase; Lymphoma, B-Cell; Male; Osteocalcin; Parathyroid Hormone; Parathyroid Hormone-Related Protein; Prednisolone; Procarbazine; Proteins

1992